![Differential Activation of p53 by the Various Adducts of Mitomycin C* - Journal of Biological Chemistry Differential Activation of p53 by the Various Adducts of Mitomycin C* - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9883dce5-5b8d-4aa1-917b-165ee9a22008/grfc1.jpg)
Differential Activation of p53 by the Various Adducts of Mitomycin C* - Journal of Biological Chemistry
![LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An In Vitro/ In Vivo Study | Bentham Science LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An In Vitro/ In Vivo Study | Bentham Science](http://www.eurekaselect.com/images/graphical-abstract/acamc/19/11/010.jpg)
LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An In Vitro/ In Vivo Study | Bentham Science
![Frontiers | Mitomycin C Inhibits Esophageal Fibrosis by Regulating Cell Apoptosis and Autophagy via lncRNA-ATB and miR-200b | Molecular Biosciences Frontiers | Mitomycin C Inhibits Esophageal Fibrosis by Regulating Cell Apoptosis and Autophagy via lncRNA-ATB and miR-200b | Molecular Biosciences](https://www.frontiersin.org/files/Articles/675757/fmolb-08-675757-HTML/image_m/fmolb-08-675757-g006.jpg)
Frontiers | Mitomycin C Inhibits Esophageal Fibrosis by Regulating Cell Apoptosis and Autophagy via lncRNA-ATB and miR-200b | Molecular Biosciences
![Frontiers | Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience | Oncology Frontiers | Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience | Oncology](https://www.frontiersin.org/files/Articles/423301/fonc-08-00544-HTML/image_m/fonc-08-00544-g004.jpg)
Frontiers | Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience | Oncology
![Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients - Golan - 2015 - Cancer Medicine - Wiley Online Library Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients - Golan - 2015 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/69e5e055-5970-4413-887e-55e6a88ec97f/cam4491-toc-0001-m.jpg)
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients - Golan - 2015 - Cancer Medicine - Wiley Online Library
![Characterization of a quinone reductase activity for the mitomycin C binding protein (MRD): Functional switching from a drug-activating enzyme to a drug-binding protein | PNAS Characterization of a quinone reductase activity for the mitomycin C binding protein (MRD): Functional switching from a drug-activating enzyme to a drug-binding protein | PNAS](https://www.pnas.org/content/98/3/926/F1.large.jpg)
Characterization of a quinone reductase activity for the mitomycin C binding protein (MRD): Functional switching from a drug-activating enzyme to a drug-binding protein | PNAS
A New Mechanism of Action for the Anticancer Drug Mitomycin C: Mechanism-Based Inhibition of Thioredoxin Reductase | Chemical Research in Toxicology
![Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA | PNAS Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA | PNAS](https://www.pnas.org/cms/10.1073/pnas.96.18.10489/asset/1eec6ea7-65e6-4a63-9c2b-f4e3ef679250/assets/graphic/pq1890389001.jpeg)